Dr Katrine Carlsen and colleagues aimed to individualize timing of infliximab treatment in children and adolescents with inflammatory bowel disease (IBD) using a patient-managed eHealth program.
Patients with IBD, 10 to 17 years old, treated with infliximab were prospectively included.
Starting 4 weeks after their last infusion, patients reported a weekly symptom score and provided a stool sample for fecal calprotectin analysis.
Based on symptom scores and fecal calprotectin results, the eHealth program calculated a total inflammation burden score that determined the timing of the next infliximab infusion.
Quality of Life was scored by IMPACT III.
A control group was included to compare trough levels of infliximab antibodies and concentrations and treatment intervals.
|80% of patients reported increased disease control|
|Inflammatory Bowel Diseases|
Patients and their parents evaluated the eHealth program.
The researchers identified 29 patients with IBD in the eHealth group, and 21 patients with IBD in the control group.
During the control period, the team found that 94 infusions were provided in the eHealth group versus 105 infusions in the control group.
The team noted that treatment intervals were longer in the eHealth group.
Quality of Life did not change during the study.
The researchers reported that the appearance of infliximab antibodies did not differ between the 2 groups.
The research team found that 80% of patients reported increased disease control, and 63% reported an improved knowledge of the disease.
Dr Carlsen's team comments, "Self-managed, eHealth-individualized timing of infliximab treatments, with treatment intervals of 4 to 12 weeks, was accompanied by no significant development of infliximab antibodies."
"Patients reported better control and improved knowledge of their IBD."